Related Experiment Video
Updated: Jul 14, 2026

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
Published on: November 26, 2015
A variant epidermal growth factor receptor protein is similarly expressed in benign hyperplastic and carcinomatous
E O Olapade-Olaopa1, D K Moscatello, E H MacKay
1Department of Urology, Leicester General Hospital, Leicester, UK. okeoffa@yahoo.com
Background And Objective:
Anti-epidermal growth factor receptor strategies are now established in cancer treatment We have recently described the presence of EGFRvIII (a variant EGFR) in prostatic tumours from UK white men and this is now a target for anti-prostate cancer treatments. However, there has been no report on the expression of this abnormal protein in black men.
Materials And Methods:
We determined EGFRvIII expression in sections of normal, benign hyperplastic (BPH) and carcinomatous (CaP) prostatic archival tissues from Nigerian men and UK white men using streptavidin immunohistochemical techniques. The EGFRvIII immunoreactivity was scored visually using a semi-quantitative method and the results compared statistically.
Results:
EGFRvIII expression increased with increasing malignancy in both study populations (CaP > BPH > Normal p, <0.0001). Furthermore, EGFRvIII expression was similar in both BPH and CaP tissues in black and white men (p, 0.86 and 0.31 respectively).
Conclusion:
These results demonstrate that EGFRvIII immunoreactivity in prostatic tumours in black men is similar to that in white men. Anti-cancer treatments directed at the EGFRvIII should be equally effective in men from both subpopulations.
Insights
Epidermal Growth Factor Receptor variant III (EGFRvIII) expression in prostate cancer is similar in black and white men. This suggests that EGFRvIII-targeted therapies may be equally effective across diverse populations.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Anti-epidermal growth factor receptor (EGFR) strategies are established cancer treatments.
- EGFRvIII, a variant EGFR, is a target for prostate cancer treatments.
- Previous studies identified EGFRvIII in UK white men but not in black men.
Purpose of the Study:
- To determine EGFRvIII expression in prostatic tissues from Nigerian (black) and UK white men.
- To compare EGFRvIII expression levels in normal, benign hyperplastic (BPH), and carcinomatous (CaP) prostate tissues between ethnic groups.
Main Methods:
- Utilized streptavidin immunohistochemical techniques on archival prostatic tissue sections.
- Employed a semi-quantitative visual scoring method for EGFRvIII immunoreactivity.
- Performed statistical comparisons of EGFRvIII expression between normal, BPH, and CaP tissues in both populations.
Main Results:
- EGFRvIII expression significantly increased with increasing prostatic malignancy (CaP > BPH > Normal; p < 0.0001) in both populations.
- EGFRvIII expression levels were statistically similar in both benign hyperplastic and carcinomatous prostate tissues between black and white men (p = 0.86 and p = 0.31, respectively).
Conclusions:
- EGFRvIII immunoreactivity in prostate tumors is comparable between black and white men.
- Anti-cancer treatments targeting EGFRvIII are expected to demonstrate similar efficacy in both subpopulations.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
Related Concept Videos
Mitogens and the Cell Cycle
The Ras Gene
Ras is a superfamily...
Abnormal Proliferation
Epistasis